Efficacy of Topical Finasteride 0.25% With Minoxidil 5% Versus Topical Minoxidil 5% Alone in Treatment of Male Pattern Androgenic Alopecia.

IF 1.5 4区医学 Q3 DERMATOLOGY Journal of Drugs in Dermatology Pub Date : 2024-11-01 DOI:10.36849/JDD.7826

Nazia Asad, Maria Naseer, Rabia Ghafoor

{"title":"Efficacy of Topical Finasteride 0.25% With Minoxidil 5% Versus Topical Minoxidil 5% Alone in Treatment of Male Pattern Androgenic Alopecia.","authors":"Nazia Asad, Maria Naseer, Rabia Ghafoor","doi":"10.36849/JDD.7826","DOIUrl":null,"url":null,"abstract":"Background: Androgenetic Alopecia (AGA) (male pattern hair loss) is the most common form of alopecia in men, affecting 30% of men by the age of 30 years and 50% by the age of 50 years.Objective: To compare the efficacy of topical finasteride 0.25% with minoxidil 5% versus topical minoxidil 5% alone in the treatment of male pattern androgenic alopecia.Methods: A total of 164 male patients aged between 30 and 60 years, presenting with androgenic alopecia of more than 2 months duration, were included in this single-blind study conducted at the Department of Dermatology, JPMC, Karachi. The patients were randomly divided into two groups: Group A (topical finasteride 0.25% with minoxidil 5%) and Group B (topical minoxidil 5% alone). Patients were followed up for 12 weeks, and hair regrowth was assessed at each visit.Results: The mean age in Group A was 33.99±5.97 years, and in Group B, it was 33.91±5.71 years. At baseline, the mean salt score was 1.8±0.7 in both groups. The efficacy of the treatment was significantly higher in Group A (86.7%) compared to Group B (69.1%; P=0.006).Conclusion: The combination of topical finasteride 0.25% with minoxidil 5% provides superior efficacy in the treatment of male pattern androgenic alopecia compared to topical minoxidil 5% alone. These findings support the use of this combination therapy as a potential treatment option for patients with androgenic alopecia. J Drugs Dermatol. 2024;23(11):1003-1008. doi:10.36849/JDD.7826.","PeriodicalId":15566,"journal":{"name":"Journal of Drugs in Dermatology","volume":"23 11","pages":"1003-1008"},"PeriodicalIF":1.5000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Drugs in Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.36849/JDD.7826","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Androgenetic Alopecia (AGA) (male pattern hair loss) is the most common form of alopecia in men, affecting 30% of men by the age of 30 years and 50% by the age of 50 years.

Objective: To compare the efficacy of topical finasteride 0.25% with minoxidil 5% versus topical minoxidil 5% alone in the treatment of male pattern androgenic alopecia.

Methods: A total of 164 male patients aged between 30 and 60 years, presenting with androgenic alopecia of more than 2 months duration, were included in this single-blind study conducted at the Department of Dermatology, JPMC, Karachi. The patients were randomly divided into two groups: Group A (topical finasteride 0.25% with minoxidil 5%) and Group B (topical minoxidil 5% alone). Patients were followed up for 12 weeks, and hair regrowth was assessed at each visit.

Results: The mean age in Group A was 33.99±5.97 years, and in Group B, it was 33.91±5.71 years. At baseline, the mean salt score was 1.8±0.7 in both groups. The efficacy of the treatment was significantly higher in Group A (86.7%) compared to Group B (69.1%; P=0.006).

Conclusion: The combination of topical finasteride 0.25% with minoxidil 5% provides superior efficacy in the treatment of male pattern androgenic alopecia compared to topical minoxidil 5% alone. These findings support the use of this combination therapy as a potential treatment option for patients with androgenic alopecia. J Drugs Dermatol. 2024;23(11):1003-1008. doi:10.36849/JDD.7826.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

外用非那雄胺 0.25%与外用米诺地尔 5%治疗男性雄激素性脱发的疗效对比。

背景：雄激素性脱发（AGA）（男性型脱发）是男性最常见的脱发形式，30%的男性在30岁前发病，50%的男性在50岁前发病：比较非那雄胺 0.25% 与米诺地尔 5%局部外用与单用米诺地尔 5%局部外用治疗男性雄激素性脱发的疗效：卡拉奇 JPMC 皮肤科开展的这项单盲研究共纳入了 164 名年龄在 30 至 60 岁之间、病程超过 2 个月的雄激素性脱发男性患者。患者被随机分为两组：A 组（外用非那雄胺 0.25%，米诺地尔 5%）和 B 组（仅外用米诺地尔 5%）。对患者进行为期 12 周的随访，并在每次随访时对毛发生长情况进行评估：A组患者的平均年龄为33.99+5.97岁，B组患者的平均年龄为33.91+5.71岁。基线时，两组的平均盐分均为 1.8±0.7。A组的疗效（86.7%）明显高于B组（69.1%；P=0.006）：结论：非那雄胺 0.25% 与米诺地尔 5%联合外用治疗男性雄激素性脱发的疗效优于单独外用米诺地尔 5%。这些研究结果支持将这种联合疗法作为雄激素性脱发患者的一种潜在治疗选择。J Drugs Dermatol.2024;23(11):1003-1008. doi:10.36849/JDD.7826.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Drugs in Dermatology DERMATOLOGY-

CiteScore

2.20

自引率

13.30%

发文量

289

审稿时长

3-6 weeks

期刊介绍： The Journal of Drugs in Dermatology (JDD) is a peer-reviewed publication indexed with MEDLINE®/PubMed® that was founded by the renowned Dr. Perry Robins MD. Founded in 2002, it offers one of the fastest routes to disseminate dermatologic information and is considered the fastest growing publication in dermatology. We present original articles, award-winning case reports, and timely features pertaining to new methods, techniques, drug therapy, and devices in dermatology that provide readers with peer reviewed content of the utmost quality. Our high standards of content are maintained through a balanced, peer-review process. Articles are reviewed by an International Editorial Board of over 160 renowned experts.